Biotech

Category / Pharmaceuticals & Biotech / Biotech

Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study

BERKELEY, CA: ...

Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting

SAN FRANCISCO, CA: ...

Atossa Genetics Inc. Announces Successful Closure of FDA Inspections

SEATTLE, WA: ...

Ally Pharma US Executes Merger

TAMPA, FL: ...

SOHM Announces Appointing of Chair of Advisory Board Team

CORONA, CA: ...

SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

VANCOUVER, BRITISH COLUMBIA: ...

Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink

EDMONTON, ALBERTA: - Grant supports collaboration with University of Alberta to advance Ceapro's proprietary high-purity dry form Beta Glucan into an active ingredient in functional food - ...

ProMetic''s PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes

LAVAL, QUEBEC: Clinical program to commence in Q4 2014 PBI-4050 to target insulin resistance and loss of pancreatic insulin production, the fundamental mechanisms in type 2 diabetes ...

Miraculins Announces Grant Of Options

WINNIPEG, MANITOBA: ...

Theravance Biopharma Announces New Employment Inducement Awards

SOUTH SAN FRANCISCO, CA: ...

Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014

TUSTIN, CA: ...

ONL Therapeutics Announces Management Team Additions

ANN ARBOR, MI: Company Strengthens Leadership by Naming Chief Science Officer, Chief Medical Officer and SVP of Operations ...

Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014

NORWOOD, MA: Live Webcast on Wednesday, December 10, at 8:35 a.m. EST ...

Health & Wellness Companies Estimated to Spend $400 Million on Consumer Point-of-Care (POC) Communications in 2014

EVANSTON, IL: First Study of Its Kind by ZS Sizes the Fast-Growing POC Marketing Channel ...

InMed Pharmaceuticals, Inc. Retains Tiberend Strategic Advisors, Inc. as Its Investor Relations and Corporate Communications Counsel

VANCOUVER, BRITISH COLUMBIA: ...

All members:	10 565
Register today:	0
Register yesterday:	0
Members online:	0
Guests online:	72

Biotech

Category / Pharmaceuticals & Biotech / Biotech

Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study

Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting

Atossa Genetics Inc. Announces Successful Closure of FDA Inspections

Ally Pharma US Executes Merger

SOHM Announces Appointing of Chair of Advisory Board Team

SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

Ceapro Awarded Research Grant from Alberta Innovates Bio Solutions to Develop Novel Formulations for Energy Drink

ProMetic''s PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes

Miraculins Announces Grant Of Options

Theravance Biopharma Announces New Employment Inducement Awards

Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014

ONL Therapeutics Announces Management Team Additions

Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014

Health & Wellness Companies Estimated to Spend $400 Million on Consumer Point-of-Care (POC) Communications in 2014

InMed Pharmaceuticals, Inc. Retains Tiberend Strategic Advisors, Inc. as Its Investor Relations and Corporate Communications Counsel

Nerium Biotechnology Reports Restated Financial Results

West Provides Required Notice of Automatic Conversion of Debentures

Flamel Technologies Closes Sale of Development and Manufacturing Facility in Pessac, France to Recipharm AB

RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis

Titan Pharmaceuticals to Present at LD Micro Conference

Service Menu

New here

Who is online